Key points are not available for this paper at this time.
We studied the impact of the 2018 heart allocation policy change on donor characteristics and posttransplant outcomes of left ventricular assist device (LVAD) -bridged heart transplant (HT) recipients. Left ventricular assist device-bridged adult HT recipients from October 2014 to October 2022 in the United Network for Organ Sharing database were categorized into old allocation policy (OAP) and new allocation policy (NAP) cohorts. Baseline characteristics, posttransplant outcomes, and subgroup analyses of unstable and stable LVAD-bridged recipients were assessed. The study included 7, 384 HT recipients; 4, 345 (58. 8%) were transplanted in the OAP era and 3, 039 (41. 2%) in the NAP era. Old allocation policy recipients were most frequently status 1A at transplantation (71. 1%), whereas NAP recipients were most frequently status 3 (40. 0%), and status 4 (31. 9%). Median donor sequence number (DSN) was higher in the NAP versus OAP era (9 vs. 3, p < 0. 001). On multivariable analysis, NAP recipients had 20% higher 1 year mortality compared to OAP (adjusted hazard ratio aHR = 1. 20 95% confidence interval CI: 1. 04-1. 40, p = 0. 01). Status 1 or 2 recipients had 28% higher 1 year mortality compared to status 1A (aHR = 1. 28 95% CI: 1. 01-1. 63, p = 0. 04). Status 1 and 2 LVAD-supported recipients had higher mortality following the 2018 allocation change, indicating the need for closer surveillance of LVAD-bridged patients who may decompensate on the waitlist.
Akbar et al. (Fri,) studied this question.